

County Durham & Tees Valley Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 11th November 2021**

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug
- A** **Amber Specialist initiation / recommendation drug**. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- X** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Tees Valley.
- ⊘** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Tees Valley.
- **Unclassed Drug** - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
None				
2) New Requests				
None				
3) New formulations & extensions to use				
None				
4) Products considered by NICE				
TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA721: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer	✓ X			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA723: Bimekizumab for treating moderate to severe plaque psoriasis	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner.
TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer	✓ X			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA725: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA726: Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	✓ X			The formulary will reflect the TAG – NHS England is the responsible commissioner
TA727: Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	✓ X			The formulary will reflect the TAG – NHS England is the responsible commissioner
TA728: Midostaurin for treating advanced systemic mastocytosis	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA729: Sapropterin for treating hyper-phenylalaninaemia in phenylketonuria	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA730: Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)	✓ X			The formulary will reflect the TAG – NHS England is the responsible commissioner
TA731: Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)	✓ X			The formulary will reflect the TAG – CCG is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA733: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia	✓ G			The formulary will reflect the TAG – CCG is the responsible commissioner. Due to the exceptionally rapid turnaround time, the APC has agreed (by exception via email correspondence) to classify Inclisiran as a GREEN drug and to adopt NICE recommendations, with work on-going on access and its actual position in lipid management. Until these resources/training and clinical guidance are in place it should not be prescribed/administered in primary care in County Durham CCG and Tees Valley CCG.
5) Appeals against earlier decisions by the APC				
None				
6) Products considered by NTAG				
Buprenorphine prolonged release injection for opioid dependence.	✓ R			The formulary will reflect the NTAG recommendation
Lurasidone (Latuda®▼) for the treatment of schizophrenia in adults and adolescents aged 13 years and over.	✓ A			Updated recommendation now recommending use as an option for the treatment of schizophrenia only in adults and adolescents aged 13 years and over. The formulary will reflect the NTAG recommendation.
Daily vs on-demand phosphodiesterase-5 (PDE-5) inhibitors for the management of erectile dysfunction following treatment for prostate cancer.	✓ A			Updated recommendation. Tadalafil 5mg once daily now recommended as an option. The formulary will reflect the NTAG recommendation
7) Miscellaneous decisions by the APC				
Human Fibrinogen (Fibryga)	✓ R			Request supported at Sept 2021 STHFT D&T. Decision: To add to formulary as a RED drug.
Nabilone - to delete from formulary	✓			Currently included in formulary as a RED drug. Decision: to delete from formulary as not in current local or NICE pain guidelines.
Meropenem/vaborbactam combination product. (Vaborem® 1 g/1 g powder for concentrate for solution for infusion)	✓ R			Request supported at Sept 2021 STHFT D&T. Decision: To add to formulary as a RED drug.
Diazepam 2.5mg rectal tubes – to delete from formulary as discontinued	✓			Decision: to delete from formulary as discontinued.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Duloxetine 90mg and 120mg capsules	✓ ✗			Decision: To add duloxetine 90mg and 120mg GR capsules to the formulary as “DNP” with the rationale “Products which are clinically effective but where more cost-effective products are available.
Macrogol Laxatives	✓ G			Decision: To approve adding Cosmocool to the formulary with sentence to use the product with the lowest acquisition cost.
Tadalafil 5mg Once daily tablets – for erectile dysfunction	✓ A			Since generics of once daily 5mg tadalafil became available the cost has fallen from £715 per patient per annum in 2017 to £50.57 per patient per annum currently based on August 2021 Drug Tariff. (Note: 2.5mg daily tadalafil = £253 per patient per annum currently). Decision: Change once daily 5mg tadalafil from NOT APPROVED to AMBER SI as an option for the management of erectile dysfunction for patients meeting the SLS criteria. Oral 2.5mg tadalafil is not recommended on the basis of cost. To remain as NOT APPROVED for BPH.
BAD List of Dermatology Specials	✓			Decision: approved adding a sub-chapter to the dermatology chapter of the formulary for the BAD Specialist List with a link to the current BAD list and table with the RAG status for the specials that are prescribed locally.

The following guidelines were presented to and approved at the November 2021 meeting of the APC:

- CD&T APC Prescribing Guidance for Non-Valvular Atrial Fibrillation.
- CD&T APC Pain Guidelines for Non-Cancer Pain – reviewed & updated.
- CD&T APC Emollient Prescribing for Dry Skin Conditions – reviewed & updated.
- NE Diabetes Network – Top Tips and Recommendations for use of Sodium Glucose Co-transporter 2 inhibitors (SGLT2i) in people with Type 2 Diabetes (T2DM)

The following shared care guidelines were presented to and approved at the November 2021 meeting of the APC:

- TEWV Aripiprazole LAI - reviewed & updated.
- TEWV Paliperidone LAI - reviewed & updated.

Other documents presented to and approved at the November 2021 meeting of the APC:

- TEWV Depression Pathway Handy Hints – reviewed & updated.
- TEWV Safety Guidance Antipsychotic Depot injections on Admission to an Acute Hospital Ward.
- CD&T Formulary Subgroup Terms of Reference – reviewed & updated.